Roche dives further into cancer cell therapy with Adaptimmune dealRoche has largely been a spectator on the side lines as other drugmakers have embraced cell therapies for Share XRoche dives further into cancer cell therapy with Adaptimmune dealhttps://pharmaphorum.com/news/roche-dives-further-into-cancer-cell-therapy-with-adaptimmune-deal/
AC Immune claims half a win for tau drug in Alzheimer’s trialShares in AC Immune leaped today after the company said its tau-targeting Alzheimer’s disease candidate semorinemab hit one Share XAC Immune claims half a win for tau drug in Alzheimer’s trialhttps://pharmaphorum.com/news/ac-immune-claims-half-a-win-for-tau-drug-in-alzheimers-trial/
Amid Actemra shortage, WHO asks Roche to ensure equitable accessRoche’s arthritis drug Actemra has become a key treatment for people with severe COVID-19, leading to shortages, and Share XAmid Actemra shortage, WHO asks Roche to ensure equitable accesshttps://pharmaphorum.com/news/amid-actemra-shortage-who-asks-roche-to-ensure-equitable-access/
RNAi biotech Atalanta debuts with $110m plus Biogen and Roche CNS tie-upsUS biotech Atalanta Therapeutics has come out of stealth mode backed with $110m from Biogen and Roche, who Share XRNAi biotech Atalanta debuts with $110m plus Biogen and Roche CNS tie-upshttps://pharmaphorum.com/news/rnai-biotech-atalanta-debuts-with-110m-plus-biogen-and-roche-cns-tie-ups/
AC Immune poleaxed on Alzheimer’s study failShares in AC Immune have collapsed after partner Genentech revealed its tau-targeting Alzheimer’s drug semorinemab had flunked a Share XAC Immune poleaxed on Alzheimer’s study failhttps://pharmaphorum.com/news/ac-immune-poleaxed-on-alzheimers-study-fail/
Amgen’s cancer biosimilars stay on US market as court battle with Roche endsAmgen has scored yet another home run in the US courts, this time seeing off a legal challenge Share XAmgen’s cancer biosimilars stay on US market as court battle with Roche endshttps://pharmaphorum.com/news/amgens-cancer-biosimilars-stay-on-us-market-as-court-battle-with-roche-ends/
Roche hops on Bicycle’s drug discovery platform for cancerRoche’s recent spate of billion-dollar plus alliances has continued with a deal with UK biotech Bicycle Therapeutics – Share XRoche hops on Bicycle’s drug discovery platform for cancerhttps://pharmaphorum.com/news/roche-hops-on-bicycles-drug-discovery-platform-for-cancer/
The promise and pitfalls of molecular testing in oncologyGreat strides have been made in the diagnosis and treatment of cancer. However, a variety of challenges remain Share XThe promise and pitfalls of molecular testing in oncologyhttps://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/research-partnership-molecular-testing-cancer/
Genentech extends small-molecule R&D with three platform dealsRoche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its Share XGenentech extends small-molecule R&D with three platform dealshttps://pharmaphorum.com/news/genentech-extends-small-molecule-rd-with-three-platform-deals/
